دورية أكاديمية
أعرض في EDS

Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.

التفاصيل البيبلوغرافية
العنوان: Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.
المؤلفون: Bogari HA; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Elhady SS; Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Darwish KM; Department of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Refaey MS; Department of Pharmacognosy, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt., Mohamed RA; Department of Aquaculture, Faculty of Aquatic and Fisheries Sciences, Kafrelsheikh University, Kafrelsheikh 33516, Egypt., Abdelhameed RFA; Department of Pharmacognosy, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt.; Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Almalki AJ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Aldurdunji MM; Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, P.O. Box 13578, Makkah 21955, Saudi Arabia., Lashkar MO; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alshehri SO; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Malatani RT; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Yamada K; Garden for Medicinal Plants, Graduate School of Biomedical Sciences, Nagasaki University, Bunkyo-machi 1-14, Nagasaki 852-8521, Japan., Khedr AIM; Department of Pharmacognosy, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt.
المصدر: Metabolites [Metabolites] 2023 Jan 21; Vol. 13 (2). Date of Electronic Publication: 2023 Jan 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101578790 Publication Model: Electronic Cited Medium: Print ISSN: 2218-1989 (Print) Linking ISSN: 22181989 NLM ISO Abbreviation: Metabolites Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مستخلص: Cancer is the leading cause of death globally, with an increasing number of cases being annually reported. Nature-derived metabolites have been widely studied for their potential programmed necrosis, cytotoxicity, and anti-proliferation leading to enrichment for the modern medicine, particularly within the last couple of decades. At a more rapid pace, the concept of multi-target agents has evolved from being an innovative approach into a regular drug development procedure for hampering the multi-fashioned pathophysiology and high-resistance nature of cancer cells. With the advent of the Red Sea Penicillium chrysogenum strain S003-isolated indole-based alkaloids, we thoroughly investigated the molecular aspects for three major metabolites: meleagrin (MEL), roquefortine C (ROC), and isoroquefortine C (ISO) against three cancer-associated biological targets Cdc-25A, PTP-1B, and c-Met kinase. The study presented, for the first time, the detailed molecular insights and near-physiological affinity for these marine indole alkaloids against the assign targets through molecular docking-coupled all-atom dynamic simulation analysis. Findings highlighted the superiority of MEL's binding affinity/stability being quite in concordance with the in vitro anticancer activity profile conducted via sulforhodamine B bioassay on different cancerous cell lines reaching down to low micromolar or even nanomolar potencies. The advent of lengthy structural topologies via the metabolites' extended tetracyclic cores and aromatic imidazole arm permitted multi-pocket accommodation addressing the selectivity concerns. Additionally, the presence decorating polar functionalities on the core hydrophobic tetracyclic ring contributed compound's pharmacodynamic preferentiality. Introducing ionizable functionality with more lipophilic characters was highlighted to improve binding affinities which was also in concordance with the conducted drug-likeness/pharmacokinetic profiling for obtaining a balanced pharmacokinetic/dynamic profile. Our study adds to the knowledge regarding drug development and optimization of marine-isolated indole-based alkaloids for future iterative synthesis and pre-clinical investigations as multi-target anticancer agents.
References: J Biol Chem. 2003 Apr 4;278(14):12406-14. (PMID: 12547827)
Pharm Biol. 2015 Jul;53(7):1030-4. (PMID: 25609152)
Cell. 1998 May 15;93(4):617-25. (PMID: 9604936)
Front Pharmacol. 2018 Apr 26;9:309. (PMID: 29755344)
Eur J Med Chem. 2013 Jul;65:112-8. (PMID: 23702473)
J Med Chem. 2014 Jun 12;57(11):4427-53. (PMID: 24320965)
Drug Discov Today. 2007 May;12(9-10):373-81. (PMID: 17467573)
Bioorg Med Chem Lett. 2000 Jun 5;10(11):1155-8. (PMID: 10866370)
Science. 1994 Mar 11;263(5152):1397-404. (PMID: 8128219)
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17783-8. (PMID: 17095602)
Bioorg Med Chem Lett. 2019 May 1;29(9):1094-1098. (PMID: 30833107)
J Thorac Oncol. 2016 Aug;11(8):1242-1245. (PMID: 27343442)
Eur J Med Chem. 2018 Jan 1;143:1103-1138. (PMID: 29157685)
J Chem Inf Model. 2021 Aug 23;61(8):3891-3898. (PMID: 34278794)
Biomed Pharmacother. 2018 Sep;105:233-245. (PMID: 29859466)
Drug Discov Today Technol. 2004 Dec;1(4):337-41. (PMID: 24981612)
Tumour Biol. 2014 Mar;35(3):2503-12. (PMID: 24234332)
J Biol Chem. 2002 Mar 29;277(13):11190-200. (PMID: 11805096)
Front Pharmacol. 2021 Aug 17;12:702611. (PMID: 34483905)
J Chem Theory Comput. 2010 Sep 1;6(10):3048-3057. (PMID: 21221418)
Biochemistry. 2007 Mar 27;46(12):3595-604. (PMID: 17328562)
Bioorg Chem. 2018 Feb;76:154-165. (PMID: 29175587)
Bioorg Chem. 2022 Jun;123:105770. (PMID: 35395446)
Nat Prod Commun. 2013 Mar;8(3):329-32. (PMID: 23678803)
J Med Chem. 2009 Feb 26;52(4):943-51. (PMID: 19199650)
Biomolecules. 2019 Sep 12;9(9):. (PMID: 31547354)
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. (PMID: 22270953)
J Phys Chem B. 2012 Jul 26;116(29):8722-31. (PMID: 22494262)
Annu Rev Pharmacol Toxicol. 2002;42:209-34. (PMID: 11807171)
Mol Cell Biochem. 2016 May;416(1-2):33-46. (PMID: 27038604)
Int J Mol Sci. 2019 Mar 19;20(6):. (PMID: 30893780)
J Immunol Methods. 1997 Oct 27;208(2):151-8. (PMID: 9433470)
Drug Discov Today. 2003 Jan 1;8(1):12-6. (PMID: 12546981)
Methods Mol Biol. 2020;2114:257-268. (PMID: 32016898)
Bioorg Chem. 2020 Mar;96:103646. (PMID: 32036160)
Sci Rep. 2019 Feb 4;9(1):1335. (PMID: 30718768)
Curr Opin Chem Biol. 2008 Jun;12(3):306-17. (PMID: 18423384)
Crit Rev Biochem Mol Biol. 1998;33(1):1-52. (PMID: 9543627)
Cells. 2021 Nov 04;10(11):. (PMID: 34831237)
J King Saud Univ Sci. 2022 Jan;34(1):101707. (PMID: 34803333)
Cancer Res. 2007 Nov 1;67(21):10129-37. (PMID: 17974954)
Nat Genet. 2007 Mar;39(3):338-46. (PMID: 17259984)
Nat Rev Cancer. 2007 Jul;7(7):495-507. (PMID: 17568790)
Pharm Res. 1998 Sep;15(9):1490-4. (PMID: 9755906)
Biochemistry. 1994 Sep 20;33(37):11097-105. (PMID: 7537084)
Nat Rev Clin Oncol. 2012 May 08;9(6):314-26. (PMID: 22566105)
Nat Struct Biol. 1996 Aug;3(8):696-700. (PMID: 8756328)
J Comput Aided Mol Des. 2017 Feb;31(2):201-211. (PMID: 28074360)
Curr Med Chem. 2003 Aug;10(15):1407-21. (PMID: 12871138)
Science. 1996 May 31;272(5266):1328-31. (PMID: 8650541)
J Biomol Struct Dyn. 2020 Aug;38(13):3814-3824. (PMID: 31490104)
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13420-5. (PMID: 9391040)
Mar Drugs. 2021 Sep 24;19(10):. (PMID: 34677434)
Eur J Pharm Sci. 2020 Nov 1;154:105510. (PMID: 32801002)
J Nat Prod. 2016 May 27;79(5):1415-22. (PMID: 27120704)
J Tradit Complement Med. 2022 Jan;12(1):16-34. (PMID: 34026584)
Ecotoxicol Environ Saf. 2022 Mar 15;233:113323. (PMID: 35183811)
Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37. (PMID: 18709663)
J Biol Chem. 1996 Aug 30;271(35):21054-61. (PMID: 8702871)
J Chem Inf Model. 2014 Sep 22;54(9):2544-54. (PMID: 25181449)
Mar Drugs. 2019 Mar 19;17(3):. (PMID: 30893778)
Nucleic Acids Res. 1994 Sep;22(17):3600-9. (PMID: 7937067)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
J Biol Chem. 2001 Dec 14;276(50):47311-9. (PMID: 11584002)
Nature. 1994 Aug 18;370(6490):575-8. (PMID: 8052313)
Nat Rev Cancer. 2006 Aug;6(8):637-45. (PMID: 16862193)
Lung Cancer. 2017 Jan;103:27-37. (PMID: 28024693)
Biochem J. 2006 Oct 15;399(2):343-50. (PMID: 16784417)
Sci Rep. 2016 Jan 29;6:20107. (PMID: 26822701)
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5910-4. (PMID: 7597052)
Pharmaceuticals (Basel). 2022 Jan 18;15(2):. (PMID: 35215223)
J Chem Inf Model. 2021 Feb 22;61(2):1020-1032. (PMID: 33538596)
Lung Cancer. 2016 Dec;102:118-121. (PMID: 27987579)
J Chem Inf Model. 2010 Sep 27;50(9):1602-10. (PMID: 20735046)
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4483-4486. (PMID: 27524312)
J Biol Chem. 2008 Feb 1;283(5):2675-83. (PMID: 18055465)
Clin Transl Med. 2018 Jan 17;7(1):3. (PMID: 29340951)
J Med Chem. 2011 Sep 22;54(18):6342-63. (PMID: 21812414)
PLoS One. 2019 Jun 11;14(6):e0218125. (PMID: 31185048)
J Phys Chem B. 2018 May 31;122(21):5466-5486. (PMID: 29649876)
Biochemistry. 2003 Oct 7;42(39):11451-9. (PMID: 14516196)
J Biol Chem. 2011 Jun 10;286(23):20666-76. (PMID: 21454604)
J Biomol Struct Dyn. 2018 Apr;36(5):1195-1211. (PMID: 28393626)
J Am Chem Soc. 2004 Jan 14;126(1):396-405. (PMID: 14709107)
J Med Chem. 2002 Aug 29;45(18):3844-53. (PMID: 12190308)
Biology (Basel). 2021 May 01;10(5):. (PMID: 34062724)
J Biol Chem. 2010 May 21;285(21):15874-83. (PMID: 20236928)
J Med Chem. 2008 May 22;51(10):2879-82. (PMID: 18426196)
Molecules. 2018 Apr 23;23(4):. (PMID: 29690588)
Ann Transl Med. 2018 May;6(9):166. (PMID: 29911114)
J Chem Inf Model. 2014 Jul 28;54(7):1951-62. (PMID: 24850022)
J Mol Graph Model. 2021 Jul;106:107940. (PMID: 34015577)
J Chem Inf Model. 2011 Mar 28;51(3):635-46. (PMID: 21370821)
J Med Chem. 2008 Dec 25;51(24):7921-32. (PMID: 19053777)
J Cell Biol. 2008 Mar 10;180(5):957-71. (PMID: 18332219)
Protein Pept Lett. 2014;21(1):90-3. (PMID: 23964742)
J Med Chem. 2008 Sep 25;51(18):5533-41. (PMID: 18714978)
J Med Chem. 2001 Dec 6;44(25):4370-8. (PMID: 11728183)
J Med Chem. 2004 Jan 29;47(3):558-65. (PMID: 14736237)
Cell. 1996 Apr 19;85(2):149-58. (PMID: 8612268)
J Biomol Struct Dyn. 2022 Jul 29;:1-11. (PMID: 35903965)
Nat Prod Rep. 2011 Feb;28(2):290-344. (PMID: 21229157)
Nature. 1990 Oct 18;347(6294):631-9. (PMID: 2215695)
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25. (PMID: 14685170)
Cancer Res. 2014 Dec 1;74(23):6737-44. (PMID: 25411347)
Bioorg Chem. 2021 Nov;116:105304. (PMID: 34534756)
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1405-9. (PMID: 20093027)
Cancer Res. 2007 Mar 15;67(6):2420-4. (PMID: 17347513)
Nat Rev Drug Discov. 2007 Nov;6(11):881-90. (PMID: 17971784)
J Thorac Oncol. 2018 Apr;13(4):e49-e53. (PMID: 29128427)
Bioorg Med Chem Lett. 2004 Nov 15;14(22):5543-6. (PMID: 15482920)
ACS Omega. 2021 Dec 22;7(1):875-899. (PMID: 35036753)
J Pharm Sci. 1999 Jan;88(1):28-33. (PMID: 9874698)
Chem Rev. 2019 Feb 13;119(3):1626-1665. (PMID: 30698416)
Science. 2000 Jun 9;288(5472):1822-5. (PMID: 10846163)
Methods Enzymol. 2006;407:597-612. (PMID: 16757355)
Bioorg Med Chem. 2016 Jan 15;24(2):113-22. (PMID: 26692349)
J Biol Chem. 1996 Nov 1;271(44):27847-54. (PMID: 8910383)
J Biomol Struct Dyn. 2019 May;37(8):2165-2178. (PMID: 30044205)
فهرسة مساهمة: Keywords: Cdc-25A; PTP-1B; Penicillium chrysogenum; Red Sea fungi; anticancer activity; c-Met kinase; drug-likeness/pharmacokinetic profiling; indole-based alkaloids; molecular modelling
تواريخ الأحداث: Date Created: 20230225 Latest Revision: 20230301
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9964656
DOI: 10.3390/metabo13020162
PMID: 36837781
قاعدة البيانات: MEDLINE
الوصف
تدمد:2218-1989
DOI:10.3390/metabo13020162